

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**HST - Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over**

**Batch 69**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- Measuring health-related quality of life in children is difficult, both in the literature and in previous NICE appraisals.
- Learning disabilities are associated with type 1 neurofibromatosis therefore for some patients, an informed consent to continuing treatment may not be possible to give.
- A final potential consideration is that selumetinib is administered in tablet form. The clinical expert stated at the scoping workshop that this would prevent very young children from being prescribed selumetinib and stated that the youngest patient currently known to them is 7 years old due to the tablet formulation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Committee should ensure that relevant measurements of health-related quality of life are taken into consideration. Committee should also be mindful that all health benefits may not be captured in the QALY calculations.

Technology Appraisals: Scoping

Equality impact assessment for the proposed highly specialised technology evaluation of selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over

Issue date: June 2021

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 08/06/2021